PALI – palisade bio, inc. (US:NASDAQ)
Stock Stats
News
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) [Yahoo! Finance]
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
Palisade Bio, Inc. (NASDAQ: PALI) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $38.00 price target on the stock.
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit [Yahoo! Finance]
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit
Form S-1/A PALISADE BIO, INC.
Form SC 13G PALISADE BIO, INC. Filed by: ARMISTICE CAPITAL, LLC
Form 10-Q PALISADE BIO, INC. For: Sep 30
Form S-1 PALISADE BIO, INC.
Form 8-K PALISADE BIO, INC. For: Sep 27
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.